#mRNA-based
For readers interested in mRNA therapeutics, including mRNA-based cancer vaccines as well as a range of other types such as in vivo CAR-T therapies and genome editors, here's a recent Review www.nature.com/articles/s41...
rdcu.be/FAnmLC17TFfa
Towards mRNA therapeutics 2.0 - Nature Reviews Drug Discovery
mRNA technology is being applied to develop a new generation of therapies for rare and common diseases. This Review discusses insights from clinical studies on mRNA-based therapeutics, including enzym...
www.nature.com
November 17, 2026 at 3:05 PM
The FDA granted approval to Moderna’s mRNA-based flu vaccine, mFLUSIVA, for adults aged 50–64, and accelerated approval for adults aged 65 and older. It is NOW available for the 2026–27 flu season.
November 13, 2026 at 5:07 PM
An optimized PanFlu-IOA-based mRNA vaccine targeting hemagglutinin confers broad-spectrum protection against heterosubtypic influenza viruses in mice
www.nature.com/articles/s41...
www.nature.com
November 16, 2026 at 2:48 PM
We have more evidence that viral infections are associated with chronic illness than we do of any association with mRNA based therapies
Epstein Barr causes mononucleosis but is associated later in life with MS and several diffferen cancers
HPV - cervical cancer and prostate cancers, throat cancer
November 15, 2026 at 11:32 PM
I opted to get the new NUVAXOVID shot this morning because the pharmacist explained that it has less side effects reported. I've only had some stiffness at the injection site. I recommend it
November 15, 2026 at 12:35 AM
EMA added mRNA flu targets for 2026/27. Egg-based shots keep a different H3N2 and B strain. Not a new authorisation.

https://europepharmatoday.com/news/ema-flu-vaccine-mrna-composition-2026-2027?utm_source=bluesky&utm_medium=social&utm_campaign=ema-flu-vaccine-mrna-composition-2026-2027

#EMA
November 18, 2026 at 3:05 PM
A new mRNA-based therapy that can reawaken heart muscle cells after a heart attack from @phar.cam.ac.uk has won this year’s Postdoc Venture Creation Challenge 💙🎉

Full story 👇

www.enterprise.cam.ac.uk/news/a-new-m...
A new mRNA-based therapy that can reawaken heart muscle cells after a heart attack wins this year’s PVCC
UK company Concr’s FarrSight® platform made its predictions without seeing how patients fared. Researchers at University Health Network in Toronto then scored them against the outcomes of a randomised...
www.enterprise.cam.ac.uk
November 16, 2026 at 1:32 PM
Circular mRNA may improve CAR-T cell efficacy.

Researchers developed a scarless platform that extends CAR expression and enhances tumor cell killing, T-cell activation, and antitumor activity in preclinical models. @upenn.edu

#STTT #OpenAccess: doi.org/10.1038/s413...
November 16, 2026 at 6:07 AM
Emvena Therapeutics Receives Seed Investment From PxB Fund

Philadelphia-based Emvena secured undisclosed seed financing from the Penn-BioNTech Innovative Therapeutics Seed Fund to advance placenta-targeted mRNA medicines for preeclampsia.

bipsiq.com/emvena-thera...
November 16, 2026 at 7:00 PM
🧬 Could an mRNA-based vaccine help prevent recurrent genital herpes?

Join HCA and Lbachir BenMohamed to explore the Prime/Pull/Keep vaccine research approach.

📅 Nov. 17 | 1 PM PT / 4 PM ET

Register: us06web.zoom.us/meeting/regi...

#MRNA #HSVResearch
Welcome! You are invited to join a meeting: A Prime/Pull/Keep mRNA-Based Vaccine to Prevent Recurrent Genital Herpes with Dr. Lbachir BenMohamed. After registering, you will receive a confirmation ema...
Welcome! You are invited to join a meeting: A Prime/Pull/Keep mRNA-Based Vaccine to Prevent Recurrent Genital Herpes with Dr. Lbachir BenMohamed. After registering, you will receive a confirmation ema...
us06web.zoom.us
November 14, 2026 at 8:35 PM
DEFB1-mRNA boosted protein 2× in intestinal cells, cutting C. parvum burden by 80% without cytotoxicity; findings support mRNA-based host-directed therapy.
Induction of β-Defensin 1 via Synthetic mRNA Reduces Cryptosporidium parvum Infection in Human Intestinal Cells
Cryptosporidiosis, caused by the parasite Cryptosporidium, is a leading cause of severe diarrhea, morbidity, and mortality in immunocompromised patients and malnourished children. Because the only Food and Drug Administration–approved treatment, nitazoxanide, shows limited efficacy in these two populations, novel therapeutics for vulnerable populations are urgently needed. Host-directed therapy (HDT) is a strategy that utilizes the induction of endogenous protective molecules. Previous work has demonstrated that human Defensin 1 (DEFB1) possesses anticryptosporidial activity. In this work, we used synthetic DEFB1-mRNA to induce DEFB1 protein in human intestinal cells and evaluate its protection against Cryptosporidium parvum infection in vitro.MethodsHCT-8 cells were transfected with synthetic DEFB1-mRNA or scrambled-mRNAs complexed with Lipofectamine. Transfection efficiency was assessed using an mRNA reporter gene. Twenty-four hours posttransfection, cells were challenged with excysted C. parvum sporozoites. DEFB1 induction was quantified by serology, while parasite burden and cell viability were assessed via microscopy, RT-qPCR, and viability assays.ResultsOur results show that transfecting HCT-8 cells with DEFB1-mRNA results in a 2-fold increase in DEFB1 protein expression. This induction protects cells from C. parvum infection, achieving an 80% reduction in parasite burden with no cytotoxicity.ConclusionsThese findings highlight the potential of mRNA technology for developing HDTs against cryptosporidiosis and other enteric pathogens.
academic.oup.com
November 17, 2026 at 4:00 PM
I'm pretty sure that you have me mis-typed as anti-vax. Obvious to me that the benefits for yearly mRNA based vaccinations outweigh the risks. Now as to what age that occurs is subject to discussion.
November 16, 2026 at 12:21 AM
In an image-based CRISPR screen of over 5,000 nuclear factors, the team identified 42 genes influencing HP1α localization.

Besides HP1α itself and TRIM28, none are known heterochromatin factors. Over 70% act in RNA metabolism, including splicing and mRNA 3’-end processing.
November 16, 2026 at 4:36 PM
His trials are based upon treatment that work on the cellular level through chemical pathways. The brother expresses concerns about poor quality controls in the manufacture of mRNA vaccines, which "may" lead to long term cellular degradation. That seems to be a legitimate line of inquiry.
November 15, 2026 at 10:11 PM
In January 2016, the Gates Foundation awarded Moderna an initial $20 million grant (with a potential commitment of up to $100 million) to research mRNA-based antibody combinations for preventing HIV and other infectious diseases.
November 13, 2026 at 10:34 AM
Peptides are mRNA Gene Modifying Platforms Designed to Destroy Mitochondria
drloveariyana.substack.com/p/peptides-a...
Peptides are mRNA Gene Modifying Platforms Designed to Destroy Mitochondria
“All warfare is based on deception” - Sun Tzu
drloveariyana.substack.com
November 11, 2026 at 7:03 PM
November 11, 2026
👉 A new mRNA-based approach could help the lungs better defend themselves against viral infections!
🙂 Another encouraging news from Groupe UIG.
Read: lnkd.in/gJUuFvDW
#GroupeUIG #Biotechnology #mRNA #Innovation
November 11, 2026 at 12:28 PM
"In May last year, Robert F. Kennedy Jr., a vaccine sceptic, cancelled a $766 million contract with Moderna to develop an mRNA vaccine against H5N1 – a technology that could offer a much faster way of delivering vaccines than traditional egg-based production... 'This is how outbreaks happen'”
Is America on the brink of sparking a new flu pandemic?
Virologists fear the United States is inching closer to becoming ground zero for an H5N1 contagion

www.telegraph.co.uk/global-healt...
November 13, 2026 at 1:23 PM
Signal or noise? > AGC Biologics partners with Child's Cure Genetic Research to
pursue mRNA-based therapeutic for severe epileptic disorder -
riauone.com >> Comment below! #strategy #competitiveintelligence #marketing #pharma #competitivemarketing #biotech #healthcare #pharmaceutical
AGC Biologics partners with Child's Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder - riauone.com
AGC Biologics partners with Child's Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder  riauone.com
dlvr.it
November 11, 2026 at 4:29 AM
ADVANCE project: Development of an mRNA Vaccine Against Liver Cancer. European Innovation Council funds international research consortium involving Frankfurt-based researchers. @goetheuni.bsky.social...
weiterlesen
November 10, 2026 at 4:16 PM
In Nature, a team at Eli Lilly and Company report that CRISPR-based inactivation of ANGPTL3, a liver-produced protein that regulates blood lipid levels, lowers LDL cholesterol and triglycerides in animal models, with effects lasting up to 3 years in primates.

A clinical trial is now underway. 🧪
In Vivo CRISPR Base Editing of ANGPTL3 for Durable Lipid Lowering | Nature
Circulating concentrations of low-density lipoprotein cholesterol (LDL-C) and triglyceride-rich lipoproteins are leading risk factors for atherosclerotic cardiovascular disease1. Despite several approved lipid-lowering medications, most patients fail to achieve target lipid levels under the chronic care treatment model2,3. Here, we describe a potential single-course treatment in which an infusion of guide RNA and mRNA encoding a CRISPR adenine base editor—encapsulated within a GalNAc–lipid nanoparticle—leads to durable, liver-selective inactivation of angiopoietin-like 3 (ANGPTL3), a known...
www.nature.com
November 13, 2026 at 12:40 AM
Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in Adolescents publications.aap.org/pediatrics/a... #hvhebron #upiip #mprev [Text complet]
Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in Adolescents
BACKGROUND AND OBJECTIVES. PHH-1V, a protein-based, non-mRNA, bivalent, adjuvanted COVID-19 vaccine, has demonstrated strong immunogenicity and favorable safety as a booster in adults. This study evaluated PHH-1V as a heterologous booster in adolescents.METHODS. HIPRA-HH-3 was a phase IIb, open-label, multicenter, noninferiority trial assessing the immunogenicity and safety of PHH-1V in 240 healthy adolescents (≥ 12 to < 18 years) primed with BNT162b2. Immunogenicity (N = 90) was assessed by measuring neutralizing antibodies against SARS-CoV-2 variants and total binding antibodies in adolescent participants vs young adults (≥ 18 to ≤ 25 years) (N = 81) from a previous trial, who had also been boosted with PHH-1V. T-cell responses at day 14 post booster were also evaluated. Antibody durability and adverse events (AEs) were assessed through day 336.RESULTS. Neutralizing titers—against Omicron BA.1 (primary endpoint), WH1, Beta, and Delta variants—and total binding antibodies were significantly higher in adolescents than in young adults (P < .001), demonstrating noninferiority (margin < 1.5). T-cell responses against BA.1 and Beta also increased significantly (P < .001). Cross-variant antibody titers remained above baseline (day 0) through day 336. AEs were mostly mild/moderate, primarily injection-site pain and headache within 28 days. No related serious AEs were reported.CONCLUSIONS. As a heterologous booster in adolescents, PHH-1V is safe and elicits cellular and sustained humoral responses with cross-variant immune recognition, which support the use of PHH-1V in adolescent vaccination strategies. Data in younger and specific risk groups are still needed.
publications.aap.org
November 19, 2026 at 7:30 AM
Also the Trump admin pulled funding for actual cancer cures (based on mRNA, so too woke!) in favor of AI for surveillance and death so uhhhhh. In the US at least AI is COMPETITION with promising cancer research...
November 10, 2026 at 6:33 PM
The Veterinary Coronavirus Vaccines Landscape summarizes publicly available information on coronavirus vaccines that are in development and commercially available for domesticated animals.

Learn more about this project, featured in AAHA: https://bit.ly/4iKOKF5
November 11, 2026 at 3:35 PM
As someone with #LongCOVID, I wish I could get the annual COVID booster, but in Sweden I can't.

Sweden will also offer only the protein-based Nuvaxovid next year, no mRNA vaccines, even though the European Medicines Agency (EMA) has approved Moderna's new combined mRNA flu and COVID shot.
EMA approves combined COVID-19 and flu mRNA vaccine
The EMA approved Moderna's mRNA COVID-19 and flu vaccine, but US political battles and funding cuts threaten the future of mRNA vaccine innovation. Talha Burki reports.
www.thelancet.com
November 7, 2026 at 5:45 PM